Cargando…

Impact of diabetes duration on left ventricular mass regression with empagliflozin

AIMS: The duration of type 2 diabetes mellitus (T2DM) is an important determinant of diabetes severity. The EMPA‐HEART CardioLink‐6 trial reported significant left ventricular (LV) mass indexed to body surface area (LVMi) regression in patients treated with the sodium‐glucose cotransporter 2 inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moroney, Michael, Verma, Raj, Hibino, Makoto, Mazer, C. David, Connelly, Kim A., Yan, Andrew T., Quan, Adrian, Teoh, Hwee, Verma, Subodh, Puar, Pankaj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192246/ https://www.ncbi.nlm.nih.gov/pubmed/37038614 http://dx.doi.org/10.1002/ehf2.14357

Ejemplares similares

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
por: Verma, Raj, et al.
Publicado: (2023)

Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin
por: Puar, Pankaj, et al.
Publicado: (2023)

IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial
por: Puar, Pankaj, et al.
Publicado: (2023)

Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial
por: Barbour, William, et al.
Publicado: (2023)

Stage‐based approach to predict left ventricular reverse remodeling after mitral repair
por: Hibino, Makoto, et al.
Publicado: (2022)

The Impact of Statins on Postdischarge Atrial Fibrillation After Cardiac Surgery: Secondary Analysis from a Randomized Trial
por: Hibino, Makoto, et al.
Publicado: (2022)

SGLT2 inhibitors and cardiac remodelling: a systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials
por: Dhingra, Nitish K., et al.
Publicado: (2021)

Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes
por: Sarak, Bradley, et al.
Publicado: (2021)

Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
por: Garg, Vinay, et al.
Publicado: (2020)

Predictors of mitral valve haemodynamics after mitral valve repair for degenerative mitral regurgitation
por: Rumman, Rawan K, et al.
Publicado: (2023)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
por: Pandey, Arjun K., et al.
Publicado: (2022)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)

Endothelial cell control of thrombosis
por: Yau, Jonathan W., et al.
Publicado: (2015)

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
por: Verma, Subodh, et al.
Publicado: (2018)

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
por: Verma, Subodh, et al.
Publicado: (2018)

Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes: Translational Insights Into the Prevention of Ischemic Complications in Diabetes
por: Terenzi, Daniella C., et al.
Publicado: (2018)

Empagliflozin reduces Ca/calmodulin‐dependent kinase II activity in isolated ventricular cardiomyocytes
por: Mustroph, Julian, et al.
Publicado: (2018)

Effects on duration of post-operative ischemia and patterns of blood flow recovery in different conditions of mouse hind limb ischemia
por: Al-Mubarak, Husain A, et al.
Publicado: (2011)

Post-exercise left ventricular dysfunction measured after a long-duration cycling event
por: Serrano Ostariz, Enrique, et al.
Publicado: (2013)

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Investigation of TGFβ1-Induced Long Noncoding RNAs in Endothelial Cells
por: Singh, Krishna K., et al.
Publicado: (2016)

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
por: Butler, Javed, et al.
Publicado: (2021)

Vascular Risk Reduction in Obesity through Reduced Granulocyte Burden and Improved Angiogenic Monocyte Content following Bariatric Surgery
por: Hess, David A., et al.
Publicado: (2020)

Isolation and characterization of circulating pro-vascular progenitor cell subsets from human whole blood samples
por: Terenzi, Daniella C., et al.
Publicado: (2021)

Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2020)

Subclinical Valve Thrombosis in Sutureless Bioprosthetic Valves
por: Yanagawa, Bobby, et al.
Publicado: (2017)

Left ventricular pseudoaneurysm as a complication of left ventricular summit premature ventricular contraction ablation
por: Dandamudi, Sanjay, et al.
Publicado: (2017)

Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia
por: Sherman, Stephen E., et al.
Publicado: (2018)

Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload
por: Nakao, Masaaki, et al.
Publicado: (2021)

Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery: A Randomized Clinical Trial
por: Ha, Andrew C. T., et al.
Publicado: (2021)

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
por: Byrne, Nikole J., et al.
Publicado: (2017)

Role of Endothelium in Doxorubicin-Induced Cardiomyopathy
por: Luu, Albert Z., et al.
Publicado: (2018)

A randomized trial of icosapent ethyl in ambulatory patients with COVID-19
por: Kosmopoulos, Andrew, et al.
Publicado: (2021)

Loss of endothelial cell-specific autophagy-related protein 7 exacerbates doxorubicin-induced cardiotoxicity
por: Luu, Albert Z., et al.
Publicado: (2021)

Attenuation of Adverse Postinfarction Left Ventricular Remodeling with Empagliflozin Enhances Mitochondria-Linked Cellular Energetics and Mitochondrial Biogenesis
por: Song, Yang, et al.
Publicado: (2021)

Empagliflozin inhibits Na(+)/H(+) exchanger activity in human atrial cardiomyocytes
por: Trum, Maximilian, et al.
Publicado: (2020)

The dual role of empagliflozin: Cardio renal protection in T2DM patients
por: Shafiq, Aimen, et al.
Publicado: (2022)

Mitral Annular Dynamics and Left Ventricular Diastole
por: Lopez-Candales, Angel, et al.
Publicado: (2017)

Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin
por: Jhuo, Shih-Jie, et al.
Publicado: (2021)

Variability in vascular smooth muscle cell stretch-induced responses in 2D culture
por: Mantella, Laura-Eve, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_egskkieel8bqlons5stto1o2fo